AQXP stock forecast
Our latest prediction for Aquinox Pharmaceuticals, Inc.'s stock price was made on the Aug. 7, 2019 when the stock price was at 3.28$.
In the short term (2weeks), AQXP's stock price should outperform the market by 5.59%. During that period the price should oscillate between -8.23% and +15.39%.
In the medium term (3months), AQXP's stock price should outperform the market by 6.52%. During that period the price should oscillate between -17.80% and +37.74%.Get email alerts
Create a solid portfolio with AQXP
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.93$ per share.
The book value per share is 3.85$
Three months stock forecastAug. 7, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|